DEF: BioCardia Seeks Shareholder Approval for Equity Plan Extension, Director Elections

BioCardia, Inc. announced its 2025 Annual Meeting of Stockholders will address the election of three Class III directors, an extension and amendment of its 2016 Equity Incentive Plan, and the ratification of its independent auditor.

Summary

• The Annual Meeting of Stockholders is scheduled for Tuesday, December 2, 2025, at 9:00 a.m. Pacific Time.
• Shareholders will vote on the election of three Class III directors: Marvin Slosman, Jay M. Moyes, and Simon H. Stertzer, M.D., to serve until the 2028 annual meeting.
• A key proposal is the amendment and restatement of the 2016 Equity Incentive Plan to extend its term until October 31, 2035, and change the automatic annual share reserve increase to 4.0% of outstanding shares.
• If approved, the plan amendment would increase shares available for issuance by 424,509, based on the 10,612,734 shares outstanding as of the October 8, 2025 record date.
• The appointment of PKF San Diego, LLP as the independent registered public accounting firm for fiscal year ending December 31, 2025, is also up for ratification.
• A non-binding advisory vote on executive compensation will be held.
• The company reported a net loss of $7,946 thousand for fiscal year 2024, an improvement from $11,571 thousand in 2023 and $11,907 thousand in 2022.
• Total Shareholder Return (TSR) for a $100 investment declined significantly, from $107.73 in 2022 to $31.78 in 2023 and $21.88 in 2024.

Sentiment

Score: 4

Explanation: While the company shows an improvement in reducing net loss and has successfully raised capital, the significant decline in Total Shareholder Return and the potential for substantial dilution from the expanded equity plan temper any positive sentiment. The lack of executive bonuses/equity in 2024 also raises questions about incentive alignment.

Positives

• Net loss decreased to $7,946 thousand in 2024 from $11,571 thousand in 2023, indicating an improvement in financial performance regarding loss reduction.
• The proposed extension and amendment of the 2016 Equity Incentive Plan are intended to attract and retain key personnel, which is crucial for long-term growth and success.
• The board of directors unanimously recommends voting FOR all proposals, indicating internal alignment on these strategic and governance matters.
• The company successfully raised approximately $15.42 million in gross proceeds through multiple private placements and a registered offering between February 2024 and September 2025, demonstrating continued investor support.

Negatives

• Total Shareholder Return (TSR) has significantly declined over the past three years, with a $100 investment in 2022 being worth only $21.88 by 2024, indicating poor stock performance.
• Executive compensation for 2024 shows no bonus or stock/option awards for the named executive officers, a notable change from 2023, which could impact future incentive and retention.
• The proposed increase in the share reserve for the equity incentive plan, by 4.0% of outstanding shares annually, could lead to significant shareholder dilution over time.
• Richard Krasno, Ph.D., a Class III director, will not be continuing on the board or its committees after the Annual Meeting.

Risks

• **Shareholder Dilution**: The proposed amendment to the 2016 Equity Incentive Plan to automatically increase the share reserve by 4.0% of outstanding shares annually could lead to significant dilution for existing shareholders.
• **Executive Retention**: The absence of bonus or stock/option awards for executive officers in 2024, as shown in the summary compensation table, might pose a risk to executive retention and motivation if not addressed by other compensation mechanisms.
• **Stock Price Performance**: The significant decline in Total Shareholder Return (TSR) over the past three fiscal years indicates a risk of continued poor stock performance and potential investor dissatisfaction.
• **Dependence on Capital Raises**: The company's frequent capital raises through private placements and registered offerings indicate a reliance on external funding, which could be a risk if market conditions become unfavorable or investor appetite wanes.
• **Litigation Exposure**: While a specific litigation (Boston Scientific Corp., et al., v. BioCardia Inc.) was settled, the company's past involvement in a Litigation Funding Agreement suggests potential exposure to legal proceedings as a business risk.

Future Outlook

The company aims to extend its 2016 Equity Incentive Plan until October 31, 2035, and increase the automatic annual share reserve to 4.0% of outstanding shares. This is intended to maintain a pool of shares for future grants to retain, incentivize, and recruit employees, directors, and consultants, which management believes is important for continued success and long-term stockholder value. The company expects to hold its 2026 annual meeting of stockholders on June 10, 2026.

Management Comments

• Management believes that stockholder approval of the Restated Plan is important for the company's continued success.
• The separation of the Chairman and Chief Executive Officer positions is believed to suit the talents, expertise, and experience that each of Dr. Altman and Mr. Blank bring to the Company.
• Management believes that the executive compensation information provided demonstrates alignment with stockholders' interests to support long-term value creation.

Industry Context

The proposals, particularly the extension and expansion of the equity incentive plan, are common practices in the biotechnology and medical device industries. Companies in these sectors often rely heavily on equity compensation to attract and retain highly skilled talent, given the long development cycles and significant capital requirements. The need for frequent capital raises also aligns with the typical funding challenges faced by early to mid-stage biotech companies. The focus on corporate governance, including director elections and auditor ratification, reflects standard compliance requirements for publicly traded companies.

Comparison to Industry Standards

• **Equity Incentive Plan Size**: An annual evergreen increase of 4.0% of outstanding shares for an equity incentive plan is on the higher side compared to typical industry benchmarks, which often range from 1-2% for mature companies, though higher percentages can be seen in growth-stage biotech firms.
• **Executive Compensation**: The significant reduction in bonus and equity awards for named executive officers in 2024 compared to 2023, despite a decrease in net loss, could be seen as a deviation from performance-based compensation trends in some industry segments, where executive pay often correlates with financial improvements or milestones.
• **Total Shareholder Return (TSR)**: A decline from $107.73 to $21.88 for a $100 investment over two years is significantly worse than the average performance of the Nasdaq Biotechnology Index (NBI) or broader market indices like the S&P 500 during the same period, indicating substantial underperformance relative to industry and market benchmarks.
• **Capital Raising Frequency**: The multiple private placements and registered offerings within a short timeframe (2024-2025) suggest a more aggressive or frequent need for capital compared to more established or cash-flow positive companies in the medical device sector.

Management Changes

Corporate Governance

Legal Proceedings

• The company was involved in a litigation case, "Boston Scientific Corp., et al., v. BioCardia Inc., Case No. 3:19-05645-VC, U.S.D.C., N. D. Cal," which was settled on April 12, 2021.
• A Litigation Funding Agreement with BSLF, L.L.C. (an entity owned by director Andrew Blank) was used to fund the litigation and was terminated in March 2022.

Related Party Transactions

• **Litigation Funding Agreement**: In 2024, the company remitted $112,876 in credits to BSLF, L.L.C., an entity owned and controlled by Andrew Blank (director), in accordance with a settlement agreement related to a prior litigation funding.
• **February 2024 Private Placement**: Peter Altman, Ph.D. (President, CEO, Director) invested $50,000.
• **August 2024 Registered Offering**: Thomas A. Satterfield, Jr. (5% stockholder) invested $210,000; Andrew Blank (Director) invested $333,000; Jim Allen (Director) invested $150,000; Peter Altman, Ph.D. (President, CEO, Director) invested $125,000; David McClung (CFO) invested $25,000.
• **April 2025 Private Placement**: Thomas A. Satterfield, Jr. (5% stockholder) invested $150,000; Andrew Blank (Director) invested $250,000; Simon H. Stertzer, M.D. (Director) invested $200,000; Richard Krasno, Ph.D. (Director) invested $25,000; Bill Facteau (Director) invested $25,000; Peter Altman, Ph.D. (President, CEO, Director) invested $50,000; David McClung (CFO) invested $25,000.
• **June 2025 Private Placement**: Thomas A. Satterfield, Jr. (5% stockholder) invested $100,000; Andrew Blank (Director) invested $150,000; Simon H. Stertzer, M.D. (Director) invested $150,000; Peter Altman, Ph.D. (President, CEO, Director) invested $50,000; David McClung (CFO) invested $10,000.
• **September 2025 Offering**: Thomas A. Satterfield, Jr. (5% stockholder) invested $500,000; Andrew Blank (Director) invested $360,000; Simon H. Stertzer, M.D. (Director) invested $498,000; Peter Altman, Ph.D. (President, CEO, Director) invested $60,000.
• **Change of Control and Severance Agreements**: Agreements are in place with Dr. Altman and Mr. McClung, providing for severance and accelerated vesting under certain termination or change of control scenarios.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from the expanded equity incentive plan. The historical decline in Total Shareholder Return indicates negative impact on shareholder value. The multiple capital raises also suggest ongoing dilution.
• **Employees**: The extension and expansion of the equity incentive plan are designed to attract and retain employees, offering long-term incentives.
• **Directors/Executives**: Eligible to receive equity awards under the amended plan, providing incentives. Several directors and executives participated in recent capital raises, demonstrating their continued investment in the company.
• **Creditors**: The capital raises provide additional funding, potentially improving the company's liquidity and ability to meet obligations.

Next Steps

• Hold the Annual Meeting of Stockholders on December 2, 2025, to vote on director elections, equity plan amendments, auditor ratification, and executive compensation.
• File a Current Report on Form 8-K with the SEC within four business days after the Annual Meeting to disclose voting results.
• If approved, the 2016 Equity Incentive Plan will be extended until October 31, 2035, and the automatic share reserve increase will take effect.
• The company expects to hold its 2026 annual meeting of stockholders on June 10, 2026.

Key Dates

Recommendation

While the company has shown some improvement in reducing its net loss and has successfully raised capital, the significant decline in Total Shareholder Return over the past few years is a major concern. The proposed expansion of the equity incentive plan, while necessary for talent retention, also presents a risk of further dilution. Given the mixed signals—operational improvements versus poor stock performance and dilution risks—a "hold" recommendation is appropriate. Investors should monitor the impact of the equity plan, future financial results, and progress in clinical development (if applicable, though not detailed in this filing) before making further investment decisions.

Keywords

BioCardia Inc., SEC Filing, Proxy Statement, DEF 14A, Equity Incentive Plan, Stock Options, Corporate Governance, Director Election, Executive Compensation, Shareholder Meeting, Capital Raise, Biotechnology, Medical Device, Financial Reporting, Risk Management, Shareholder Dilution, Total Shareholder Return